Skip navigation

Identify the Keys to Early Commercialization • Eliminate Barriers to Market Access • Harness New Technology and Ensure Post-Launch Success

September 25-26, 2018
  • Cambridge, MA

In an increasingly complex healthcare landscape, it is more important than ever to have an early product launch plan for your drug.

Whether you are a pre-commercial biotech or an established pharmaceutical company, you’ll face many of the same challenges as you prepare the market, prepare your organization and prepare your product.

Join us for CBI’s 4th Annual Bio/Pharmaceutical Product Launch Summit and analyze each step that’s necessary to innovatively plan for a new product launch. Identify best practices, KPIs and “how to” tactics that you can take home with you.

Top Reasons to Attend:

  • Hear from experts on best practices for
    pre-commercialization planning
  • Optimize your post-launch infrastructure
  • Examine the differences between launching a rare
    disease drug, biosimilar, generic or specialty drug
  • Learn to navigate the risks and complexities involved in
    accurate budgeting and forecasting
  • Find inspiration from industry leaders on ways to create
    a clear, and concise communication platform for a
    drug candidate to improve performance
  • Take internal project management to the next level —
    build strategies to utilize across multiple departments
  • Dig into government pricing strategies as you
    prepare to go-to-market
  • Gain valuable insights on how to create a market research
    studies that support product launch activities
  • Optimize value for market access at launch
  • Draw from technology experts on ways to improve the
    serialization process, name creation and packaging design

Previous Attendee Acclaim:

I thought the conference was well prepared. All the speakers were experts in their topic and delivered their message effectively. Group interaction was also great. I learned a lot
and recommend this type of conference to anyone who is preparing to launch a product in the next 3-5 years.

Executive Director, Commercialization, Noven Pharmaceuticals